Proscia Expands Concentriq Platform with Real-World Data to Enhance Precision Medicine

Proscia has announced a new real-world data offering on its Concentriq platform, integrating over 10 million de-identified pathology images with clinical and genomic data. This addition provides life sciences organizations access to one of the most extensive repositories of such data, aiming to accelerate the development of precision therapies and diagnostics. Following a successful year-long pilot, this launch is designed to support advancements in personalized care by leveraging detailed disease profiles and AI-driven insights.

The integration of digital pathology, a field that is increasingly critical to precision medicine, allows organizations to use whole slide images, which contain billions of pixels detailing diseases like cancer. These images, when combined with clinical and genomic data, offer a new modality for understanding diseases and developing targeted treatments. Proscia's approach positions it at the intersection of pathology, AI, and real-world data, aiming to provide actionable insights that guide novel therapeutic and diagnostic development.

Proscia's real-world data offering enables life sciences organizations to leverage pathology images from one of the world's most comprehensive repositories alongside clinical and genomic data

Ben Freiberg, Ph.D., Principal Informatics Systems Lead at Genentech, highlighted the significance of this data integration:

“It’s an exciting time for the future of healthcare. Pathology is fundamental to our understanding of disease; yet it has been a missing piece of the puzzle when it comes to drug discovery and development. Proscia is leading the way in enabling life sciences organizations to tap into high-value pathology datasets as a key component of real-world data.”

Features of the New Offering:

• Multimodal Data Access: Biopharmaceutical companies can now access ready-to-use datasets that align closely with their drug development pipelines. Proscia provides highly relevant, de-identified cohorts from a diverse collection of over 10 million whole slide images, supplemented with structured data from molecular tests, pathology reports, laboratory tests, and next-generation sequencing across various therapeutic areas. The data is further enhanced with AI-computed features, ranging from hundreds to thousands per image, to generate deeper insights.

• Integration with AI and Research Workflows: Data sets are made available on Concentriq, the same AI-enabled platform that supports pathology workflows from biomarker discovery to clinical trial execution. This seamless integration allows scientists to quickly utilize the data in their research, develop proprietary AI models, and leverage Proscia’s precision medicine AI portfolio for creating new diagnostics.

• Expanded Access to Precision Diagnostics: With Concentriq's existing use among national laboratories and health systems, biopharmaceutical companies can deploy their AI-enabled precision diagnostics across a growing network. This broader reach facilitates the integration of advanced diagnostics into clinical practice, enabling better patient matching with suitable treatments.

David West, CEO of Proscia, commented on the evolving role of data in precision medicine:

“Life sciences organizations are turning to real-world data and AI to answer their biggest questions and advance precision medicine from bench to bedside. The interplay among whole slide images, clinical and genomic data, and novel therapies and diagnostics will only grow stronger. Proscia is uniquely positioned at this intersection to help our customers deliver the next generation of patient care.”

Proscia will further discuss this development in an upcoming webinar titled “From Bedside to Bench and Back: How Digital Pathology Is Fueling Precision Medicine With Unprecedented Real-World Data,” scheduled for October 30, 2024.